Vitamin B3 supplement studied for rare lung condition

NCT ID NCT07563322

Recruiting now Knowledge-focused Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether nicotinamide riboside, a form of vitamin B3, can improve how cells produce energy in people with combined pulmonary hypertension (CPH). CPH is a serious lung and heart condition with no approved treatments. Ten participants will receive both the supplement and a placebo at different times to see how it affects biological markers in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nicotinamide riboside (a form of vitamin B3)
What this could lead to: If it works, this could point toward a new way to support cell energy in people with combined pulmonary hypertension, but it is not a treatment test.
What could go wrong: This is a very small, early study with only 10 people. It looks at biological markers, not symptoms or survival, so even positive results may not lead to a real treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY HYPERTENSION

Contacts and locations

Locations

Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.